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ABSTRACT 
ENDOMETRIAL CARCINOMA – A CLINICOPATHOLOGICAL STUDY 
INTRODUCTION 
Endometrial carcinoma is the fourth most common cancer in females, 
ranking behind breast, lung and bowel cancers in the Western population. It is the 
eighth leading cause of death from malignancy in women. It is the most common 
gynaecological   malignancies in Western world. In India, cervical cancer ranks 
first among gynecological malignancies. However in recent years there is a 
increasing   trend in the incidence of endometrial carcinoma. 
AIM OF THE STUDY 
The aim of our study is to analyze various etiological factors responsible for 
endometrial carcinoma, to study the various clinical presentations, ideal 
investigations and management of endometrial carcinoma and assess the outcome 
of endometrial carcinoma. 
MATERIALS AND METHODS 
All patients who were diagnosed to have endometrial carcinoma by 
dilatation and curettage or detected after surgery by histopathological examination 
were enrolled in the study and their clinical profile was analyzed for various 
demographic details, presenting signs and symptoms, menstrual history, associated 
medical disorders and family history .Their height, weight, BMI, Clinical 
examination findings and results of various investigations were tabulated.  Details 
of surgical procedure and intraoperative findings were recorded. Patients were then 
staged as per FIGO staging and histopathological features were documented. 
Patients were then either observed as in stage I A or given appropriate adjuvant 
therapy post operatively with vaginal brachytherapy or chemoradiation for other 
stages. All patients were followed throughout the study. Data were entered into a 
standard proforma and analyzed. 
 
RESULTS 
Risk factors for endometrial carcinoma like early menarche, late menopause, 
nulliparity, infertility, are not observed among our patients but the incidence is 
increasing in our population probably because of increased obesity. Endometrioid 
adenocarcinoma is the most common histologic type noted and most of them 
presented with stage I disease .2 year survival for endometrial carcinoma is 85% 
  
CONCLUSION 
  To promote healthy lifestyle and decrease incidence of obesity among our 
population. Post menopausal hormone therapy should used along with 
progesterone to prevent endometrial stimulation. Early diagnosis and management 
can improve survival in endometrial carcinoama patients as shown in our study. 
Key words 
Endometrial carcinoma, obesity, ,hysterectomy ,lymphadenectomy ,FIGO 
staging 
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INTRODUCTION 
Endometrial carcinoma is the fourth most common cancer in 
females, ranking behind breast, lung and bowel cancers in the Western 
population. It is the eighth leading cause of death from malignancy in 
women. It is the most common gynaecological   malignancies in 
Western world. In India, cervical cancer ranks first among 
gynecological malignancies. In population based cancer registry of 
Delhi, the incidence of endometrial cancer is 4.3/ 100,000 women per 
year (ICMR).  However in recent years there is a increasing   trend in 
the incidence of endometrial carcinoma.  Probable reasons include a 
decline in the incidence of cervical cancer due to its early detection by 
increased use of PAP smear, VIA VILI and colposcopy and a rise in 
the risk factors of Endometrial carcinoma like increased longevity of 
women, obesity, changing life styles, increased incidence of diabetes 
and hypertension and use of postmenopausal hormone therapy . Since 
>70% of cases, are confined to uterus at time of diagnosis, early 
diagnosis is likely to cure endometrial cancer. Hence we are in the 
verge of understanding endometrial carcinoma and its 
clinicopathological features.  
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AIM OF THE STUDY 
1) To analyze various etiological factors responsible for 
endometrial carcinoma  
2)  To study the various clinical presentations, ideal 
investigations and management of endometrial carcinoma  
3)  To assess the outcome of endometrial carcinoma 
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REVIEW OF LITERATURE 
Gallup et al analyzed endometrial carcinoma patients  younger 
than 40 years  as compared with those 41 years of age or older  and 
found that obesity  was 43.8%,  nulliparity 44% hypertension 31.2% 
and diabetes 6.2%  among young patients and tended to have a well-
differentiated tumor, and 31.2% had polycystic ovaries.  
Connelly PJ et al studied eight hundred sixty-five patients with 
confirmed adenocarcinoma of the endometrium.  They found age at 
diagnosis was the single most important clinical determinant of 
survival. Nuclear grade was a significantly more accurate indicator 
than was histologic grade. Stage and depth of invasion were also 
important predictors of survival. 
Fanning et al studied all cases of endometrial adenocarcinoma 
treated at the Geisinger Medical Center from January 1970 to June 
1980 were reviewed in an attempt to elucidate the clinical and 
pathologic profiles of the various histologic subtypes. Histologic 
subtypes were adenocarcinoma 66%, adenoacanthoma 16%, 
adenosquamous 5%, papillary 8%, clear cell 3%, and secretory was  
2%.Adenosquamous, papillary, and clear cell have decreased 5-year 
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survival and appears to be associated with increased grade 3 
differentiation and deep myometrial invasion . 
Jobo et al analyzed patients younger than 50 years of age 
clinicopathologically in comparison with those of other age groups. 
The results were 29.3% were diagnosed in those younger than 50 
years of age .The average age of endometrial cancer was 53.6 years. 
The majority of these patients 93.4% complained of vaginal bleeding. 
History of irregular menstrual cycle was only observed in 25.6% of 
the patients with the age 50 or older, whereas it was 61.5%  with 40 
and less . Nulliparity was found in 19.8%. Hypertension was found 
more frequently in older patients, but diabetes mellitus and obesity did 
not correlate with age. Well differentiated adenocarcinoma (G1) and 
adenoacanthoma was observed frequently in younger age group. 
Endometrial hyperplasia was often combined with cancer in young 
women.  
 Gao js et al elicited that were high incidences of infertility, 
irregular menstruation, endometrial hyperplasia, obese and polycystic 
ovaries in patients aged 45 years and younger, indicating the 
relationship between endometrial carcinoma and estrogen. 
Kelsey et al did a case-control study of the epidemiology of 
endometrial cancer in women aged 45-74 years was carried out in 
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Connecticut from 1977 to 1979. In total, 167 cases and 903 controls 
were included.  The study found that use of oral contraceptives was 
associated with a decreased risk, although the decrease did not reach 
statistical significance. 
Lapinska, et al  analyzed the risk factors of endometrial 
carcinoma and found that the percentage of nulliparas was lower than 
it is described in literature (40-50%) and was 16.2% 
Iatrakis et al studied women younger than 50 years with 
endometrial cancer and found that body mass index (BMI), parity, 
type of menstrual cycles, diabetes and history of polycystic ovarian 
(PCO) syndrome are probably related to endometrial cancer in women 
younger than 50 years of age, and the strongest relation was found 
with increased BMI.  
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ANATOMY 
The uterus is situated in the pelvic cavity between the bladder 
and the rectum. It is divided into two parts the body (corpus) and the 
cervix that are separated by a slight narrowing of the uterus, known as 
the isthmus. This is the level of the internal os of the cervix. The 
cervix is divided into the supravaginal portion, which is closely 
approximated to the bladder, and the vaginal portion, which projects 
into the cavity of the vagina. The principal ligaments of support for 
the uterus are the broad ligaments, the round ligaments, the uterosacral 
ligaments, and the cardinal ligaments. 
Blood is supplied to the uterus by the uterine artery, which is a 
branch of the hypogastric artery and which enters the wall of the 
uterus at the isthmus after it crosses over the ureter. It anastomoses 
with the ovarian artery in the ovarian ligament. 
The lymphatics of the myometrium drain into the subserosal 
network of lymphatics, which coalesce into larger channels before 
leaving the uterus. Lymph flows from the fundus toward the adnexa 
and infundibulopelvic ligaments. The lymph flow from the lower and 
middle thirds of the uterus tends to spread in the base of the broad 
ligaments towards the lateral pelvic side wall . There are three 
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drainage channels from the uterus: from the fundus, with the ovarian 
vessels; in the folds of the broad ligament; along the mesosalpinx and 
fallopian tubes; and along the round ligaments to the femoral lymph 
nodes. 
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EPIDEMIOLOGY AND RISK FACTORS 
Endometrial carcinoma is a disease of the postmenopausal 
woman, although 25% of the cases occur in premenopausal patients, 
with 5% occurring in patients younger than 40 years of age(1,2). 
Average age of diagnosis is 60 years. Most of the risk factors of 
endometrial carcinoma are related to PROLONGED UNOPPOSED 
OESTROGEN   STIMULATION of the endometrium . 
 This increased risk among nulliparous women could be due to 
lack of hormonal factors during pregnancy and lactation, which 
represents a period with reduced exposure to unopposed oestrogen . 
Early menarche and late menopause expose the uterus to oestrogen of 
menstrual cycles for a long period. Infertility and irregular menstrual 
cycles cause anovulatory cycles and hence prolonged exposure to 
oestrogen with insufficient progesterone. Obesity causes excess 
oestrone from peripheral aromatisation of androstenedione. Other 
causes of long term oestrogen exposure like polycystic disease, 
functioning ovarian tumours, exogenous menopausal oestrogen 
therapy without progestins increase the risk. Use of Tamoxifen for the 
treatment of breast cancer is associated with increased risk due to the 
oestrogenic action of Tamoxifen on the endometrium. Diabetes 
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mellitus, hypertension and hypothyroidism are associated with 
endometrial carcinoma. Women with LYNCH II syndrome have 40 % 
to 60 % lifetime risk for endometrial carcinoma.A reduced risk of 
uterine cancer among smokers has been reported. Cigarette smoking 
has been linked to an earlier age at natural menopause and to reduced 
levels of endogenous estrogens. 
Risks factors for endometrial carcinoma 
Characteristics Relative  risk 
Obesity 
   >20 lb 3 
   >50 lb 10 
Nulliparous 2- 3 
Late menopause 2.4 
Diabetes mellitus 2.8 
Hypertension 1.5 
Unopposed estrogen 4-8 
Complex atypical hyperplasia 29 
Lynch II                                   20 
Tamoxifen therapy                             2-3 
 
Geographic variation in rates of uterine cancer, with high rates 
in certain industrial areas, has led to the suggestion that certain 
environmental agents may affect risk. There has been particular 
concern about a potential role for certain endocrine disruptors, 
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including dichlorodiphenyltrichloroethane (DDT). Women of upper 
socioeconomic status have been reported to be at a higher risk of 
uterine cancer. This may be partially explained by risk factors 
correlated with affluence e.g., the use of estrogen replacement therapy, 
obesity etc. 
HYPERPLASIA 
Endometrial hyperplasia includes wide range of 
morphologically and biologically altered stroma and glands of 
endometrium ranging from exaggerated physiologic status to 
carcinoma in situ. Hyperplasia is seen in a background of proliferative 
endometrium due to prolonged oestrogen stimulation without 
progesterones.  Endometrial hyperplasias cause abnormal uterine 
bleeding, can be associated with oestrogen producing tumours or 
hormone therapy and can precede or occur along with endometrial 
cancer.  Some hyperplasias may regress if the estrogenic stimulus is 
removed or in response to progestational or antiestrogenic treatment. 
The probability of progression to adenocarcinoma is related to the 
degree of architectural or cytologic atypia. Coexistent adenocarcinoma 
is present in 1% to 40% of hysterectomies performed to treat 
11 
 
hyperplasia, with the latter number reflecting the frequent co-
occurrence of carcinoma with atypical complex hyperplasia. 
Hyperplasia is classified based on architecture of glands into 
simple or complex and based on cytologic features into typical or 
atypical. The resulting classification has four categories as follows: 
simple hyperplasia (SH), complex hyperplasia (CH), simple atypical 
hyperplasia (SAH) and complex atypical hyperplasia (CAH). 
  Simple hyperplasia is composed by enlarged or cystic glands 
with irregular shapes, increased glandular to stromal ratio. There is no 
glandular crowding or cytologic atypia.  The endometrium is thicker 
than usual. Follow-up of patients with this condition reveals little or 
no progression to carcinoma. 
Complex hyperplasia has complex architecture like budding and 
infolding of crowded glands with decreased stroma and there is no 
cytologic atypia. The endometrium is increased in thickness. The two 
main features differentiating this from simple hyperplasia are the 
back-to-back glands and the intraluminal papillae. Epithelial 
pseudostratification is a frequent finding.   
12 
 
Atypical Hyperplasia is characterized by cytologic atypia 
including nuclear hyperchromatism , enlargement of the nuleus and 
increased nuclear-cytoplasmic ratio. Nuclei are irregularly sized and 
shaped with thick nuclear membrane and prominent nucleoli. The 
nuclei have irregular scattered coarse chromatin clumps with 
parachromatin clearing. 
Classification of endometrial hyperplasia 
Types of hyperplasia Progression to                                                     
cancer% 
Simple  (cystic without atypia) 1 
Complex (adenomatous without atypia) 3 
Simple (cystic with atypia) 8 
Complex (adenomatous with atypia) 29 
 
Patients with complex and atypical hyperplasia may be treated 
by hysterectomy or by periodic use of progestins, depending on age 
and reproductive desires. Hysterectomy is the preferred treatment in 
the patient with complex atypical endometrial hyperplasia. A 
progestin should be administered at least 10 to 14 days each month, 
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and endometrial biopsies should be performed at 3- to 4-month 
intervals to assess treatment results. 
CLINICAL FEATURES 
Endometrial carcinoma occurs most often in the 6th and 7th 
decades of life, with a median age at onset of 60 years. Most patients 
are postmenopausal, and the remainder are usually in the climacteric, 
or so-called perimenopausal, years.  It is estimated that 75% of the 
cases occur in patients 50 years old and older, and 95% occur in 
patients over 40 years of age. The disease, although reported in 
patients as young as age 16 years, is rare in patients younger than 30 
years of age. Abnormal vaginal bleeding is their only symptom in 
about 90% of patients and many recognize this symptom and consult 
their physician within 3 months. 10% may show leukorrhea. Pelvic 
pressure and discomfort indicate uterine enlargement or spread of 
tumour to extrauterine sites.  Less than 5 % are asymptomatic, usually 
detected as a result of evaluation of abnormal Pap smear or in USG or 
CT done for an unrelated cause or detected in uterus removed for a 
benign cause. 
Dilatation and curettage is the gold standard for evaluating 
abnormal uterine bleeding and diagnosing endometrial carcinoma. 
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Endometrial aspiration biopsy along with endocervical sampling can 
be done in the outpatient department. Results of endometrial biopsies 
are similar to  endometrial curettage(3,4) . However, the methods, 
individually or combined, may miss an existing endometrial 
carcinoma because the sampling is random and does not include the 
entire endometrium.  Hysteroscopy is accurate in identifying polyps. 
Abnormal findings are seen in only 30% to 50 % of patients in PAP 
smear and hence it is not a reliable tool for diagnosing endometrial 
cancer. 
PATHOLOGIC DIAGNOSIS 
The International Society of Gynecologic Pathologists (ISGP) 
and the WHO last revised the classification of uterine tumors in 1992. 
Mixed carcinomas with two distinctive cell types are relatively 
common, and are defined as those carcinomas in which the secondary 
component constitutes at least 10% of the neoplasm. 
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CLASSIFICATION OF ENDOMETRIAL CARCINOMA 
Endometrioid adenocarcinoma 
Variants: 
Papillary or Villoglandular variant 
Secretory carcinoma 
Adenocarcinoma with squamous differentiation 
Mucinous Carcinoma 
Papillary Serous Carcinoma 
Clear-Cell Carcinoma 
Squamous Carcinoma 
Undifferentiated Carcinoma 
Mixed Carcinoma 
 
FIGO definition for GRADING of endometrial carcinoma: 
 G1-5% or less of a nonsquamous or nonmorular solid growth 
pattern. 
 G2-6% to 50% of a nonsquamous or nonmorular solid growth 
pattern. 
 G3-More than 50% of a nonsquamous or nonmorular solid 
growth pattern. 
 Notable nuclear atypia, inappropriate for the architectural grade, 
raises a grade 1(G1) or grade 2(G2) tumor by one grade. 
 In serous adenocarcinomas, clear-cell adenocarcinomas and 
squamous-cell carcinomas, nuclear grading takes precedence. 
 Adenocarcinomas with squamous differentiation are graded 
according to the nuclear grade of the glandular component. 
 HISTOLOGIC TYPES
Endometrioid Adenocarcinoma
Endometrioid adenocarcinoma constitutes 75% to 80% of the 
endometrial cancer. Characteristically, tumour is made up of glands 
similar to normal glands of the endometrium. The glands are lined by 
tall columnar cells and nucleus is basally oriented. There is no 
intracytoplasmic mucin(5,6). As the tumour becomes less 
differentiated it contains increased solid areas, decreased gland 
formation and increased nuclear atypia.
                        
 
 
 
 
 
Gross Specimen 
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Cut Section of the Uterus 
showing the tumour 
 
  Endometrioid  Carcinoma 
     Irregularly placed glands
Variants  
Adenocarcinoma with Squamous Differentiation
Foci of squamous differentiation are found in about 15 % to 
25% of endometrial adenocarcinomas(7) . Historically, the tumors 
were sometimes separated into adenoacanthoma or adenosquamous 
carcinoma based on whether the squamous
histologically benign or malignant. 
Villoglandular or Papillary variant
Villoglandular configuration is present in 2 % of endometrioid 
adenocarcinoma characterized by neoplastic columnar cells covering 
delicate fibrovascular cores and the tumor cells architecturally 
17 
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resemble those of other endometrioid adenocarcinomas, with which 
they are often admixed. In the largest study to date, villoglandular 
carcinomas were better differentiated than endometrioid carcinomas, 
but the age at diagnosis, depth of myometrial invasion, nodal spread, 
and survival were similar to those of endometrioid carcinomas, 
justifying their classification as a subtype of endometrioid 
adenocarcinoma(8) . 
 
Villoglandular variant of Endometrioid Carcinoma 
Secretory Carcinoma 
Secretory carcinoma is a variant and comprises >1% of 
endometrioid carcinoma. Histology shows well-formed glands with 
columnar epithelium containing intracytoplasmic vacuoles similar to 
secretory endometrium. The intracellular secretions are not mucin but 
glycogen. The cellular features of secretory carcinoma differentiate it 
from clear-cell carcinoma, which is more papillary with more 
pleomorphic nuclei. By its lack of mucin, secretory carcinoma may be 
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differentiated from mucinous carcinoma. Recognition of secretory 
carcinoma is important because it has a less virulent clinical course   
although the clinical profile of patients is similar to that of patients 
with adenocarcinoma. 
Mucinous Carcinoma 
Mucinous adenocarcinoma is rare in the endometrium   
accounting for about 5 % in contrast to its high frequency in the 
endocervix. The characteristic cellular pattern should represent over 
50% of the entire tumor. Typically, there are papillary processes and 
cystically dilated glands lined by columnar or pseudostratified 
columnar epithelium. Primary endometrial carcinoma is differentiated 
from endocervical adenocarcinoma by merging of tumour with normal 
endometrium, foamy stromal cells, presence of metaplastic squamous 
epithelium or areas of typical endometrioid adenocarcinoma. 
 
 
 
 
Mucinous Carcinoma 
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Serous Carcinoma 
Serous carcinoma of the endometrium is similar to serous 
carcinoma of the ovary and fallopian tube due to its papillary growth 
and cellular features.  It occurs in older women in an advanced 
stage(9). Fibrous papillary fronds are lined by epithelial cells, which 
are almost devoid of cytoplasm, but which manifest stratification, 
atypism, pleomorphism, mitotic figures, and bizarre forms. It is 
differentiated from clear-cell carcinoma by greater degree of papillary 
processes, increased nuclear atypia, and reduced cytoplasm in 
papillary serous carcinoma. Psammoma bodies are frequently 
observed in serous carcinoma, but solid growth is more common in 
clear-cell carcinoma. 
Serous carcinoma represents approximately 10% of endometrial 
carcinomas, which is fortunate because it is an aggressive tumor. The 
tumors often deeply invade the myometrium, and unlike typical 
endometrioid adenocarcinoma, there is a propensity for peritoneal 
spread. Endometrial intraepithelial carcinoma (EIC)(10,11,12,)is a  
distinctive lesion that is specifically associated with serous carcinoma. 
It usually arises from atrophic polyps rather than hyperplasia and there 
is no epidemiological relationship with oestrogen exposure. 
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Clear-Cell Carcinoma 
Clear-cell adenocarcinoma constitute less than 4% of all 
endometrial carcinoma. The hallmark of clear-cell carcinoma is the 
presence of neoplastic cells with optically clear cytoplasm, reflecting 
an abundance of glycogen. Four basic architectural patterns of clear-
cell adenocarcinoma exist, including solid, glandular, tubulocystic, 
and papillary, but most cases display an admixture of patterns and 
lining cells have a hobnail appearance. In contrast with the 
diethylstilbestrol (DES) related clear-cell carcinomas of the vagina 
and cervix, clear-cell carcinoma of the endometrium is almost 
exclusively a disease of menopausal women. 5-year survival rate is 
only about 33 % to 65% due to its aggressive nature. 
 
 
 
 
 
 
Clear-Cell Carcinoma 
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Squamous Carcinoma 
Although focal squamous differentiation is common in 
endometrial adenocarcinoma, pure squamous carcinoma of the 
endometrium is extremely rare, representing less than 1% of 
endometrial carcinoma. Most patients are postmenopausal. Squamous 
carcinoma of the endometrium is established as primary in the 
endometrium after a cervical origin is ruled out. It should not be 
associated with benign or malignant squamous epithelium of cervix. It 
is associated with pyometra, cervical stenosis, and inflammation. 
Tumour has poor prognosis with survival rate of 36 %. 
Undifferentiated Carcinoma 
Undifferentiated carcinoma of the endometrium has no 
glandular, squamous, or sarcomatous differentiation in routinely 
stained sections. Some cases contain argyrophilic cells or 
neurosecretory granules demonstrated by immunohistochemical stains 
or electron microscopy. Glassy-cell carcinoma comprises less than 1% 
of endometrial tumours. It is characterized by cytoplasm that has a 
ground-glass appearance, as in the cervix. Although few cases have 
been reported, like serous and clear-cell carcinomas, glassy-cell 
carcinoma appears to be aggressive. 
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Mixed Cell Type 
If an endometrial carcinoma manifests two or more different 
cell types, each representing at least 10% or more of the tumor, the 
term mixed cell type is appropriate. 
Simultaneous Tumors 
Simultaneous tumours of the endometrium and ovary are the  
most common simultaneously occurring malignancies of the genital 
tract with an incidence of 1.4% to 3.8 %. Mostly both are grade I 
tumours of early stage with good prognosis. Abnormal uterine 
bleeding is the common symptom in these patients .The ovarian 
tumour is usually diagnosed incidentally and at an early stage because 
of the symptomatic uterine carcinoma and hence has better prognosis. 
If the endometrial tumor is less than 5 cm in diameter, the ovarian 
lesion is unilateral, invasion is less than the middle third, vessels are 
not involved, and the endometrial carcinoma is well differentiated, 
metastasis to the ovary is unlikely. 
CLINICAL STAGING 
Clinical staging should be done only in patients who are not 
eligible for surgical staging due to poor medical condition. With 
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advanced anaesthesia techniques and surgical methods almost all 
patients are medically fit for surgical therapy. Few patients may not be 
eligible for surgical staging because of involvement of cervix, 
parametrium ,  bladder or rectum or metastasis to distant sites. 
CLINICAL STAGING, FIGO, 1971    
Stage Characteristics 
I Carcinoma is confined to the corpus 
IA Length of the uterine cavity is 8 cm or less 
IB Length of the uterine cavity is more than 8 cm 
II Carcinoma involves the corpus and cervix 
III Carcinoma extends outside the uterus but not outside the true 
pelvis 
IV Carcinoma extends outside the true pelvis or involves the 
bladder or rectum 
 
Important prognostic factors like histologic type and grade  can 
be assessed before surgery, although grade,  determined by dilatation 
and curretage, has 31% inaccuracy rate when compared to 
histopathological grade while grade 3 tumors are  50% inaccurate. 
This led the FIGO, in 1988, to define endometrial cancer as a 
surgically staged disease, including many of the prognostic factors 
into the staging process. 
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FIGO STAGING 
INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS 
(FIGO)2008  SURGICAL STAGING SYSTEM FOR ENDOMETRIAL 
CARCINOMA 
I-  Tumor confined to the corpus uteri 
IA  -Tumor limited to endometrium or invades less than one-half of 
the myometrium 
IB  -Tumor invades one-half or more of the myometrium 
II-  Tumor invades stromal connective tissue of the cervix but does 
not extend beyond uterus* 
IIIA - Tumor involves serosa and/or adnexa (direct extension or 
metastasis)** 
IIIB  -Vaginal involvement (direct extension or metastasis) or 
parametrial involvement** 
IIIC  -Metastases to pelvic and/or para-aortic lymph nodes** 
IIIC1 - Regional lymph node metastasis to pelvic lymph nodes 
(positive pelvic nodes) 
IIIC2 - Regional lymph node metastasis to paraaortic lymph nodes, 
with or without positive pelvic lymph nodes 
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IV -Tumor invades bladder and/or bowel mucosa, and/or distant 
metastases 
IVA -Tumor invades bladder mucosa and/or bowel (bullous edema is 
not sufficient to classify a tumor as IV) 
IVB -Distant metastasis (includes metastasis to inguinal lymph nodes 
intra-peritoneal disease, or lung, liver, or bone) 
*    Endocervical glandular involvement only should be considered as 
Stage I and  no longer as Stage II. 
**   Positive cytology has to be reported separately without changing 
the stage. 
  
PATHOLOGIC FACTORS OF PROGNOSTIC SIGNIFICANCE 
Although disease stage is the most significant prognostic 
variable affecting survival, other individual prognostic factors are 
discussed below. 
Histologic Cell Types  
10 % of endometrial cancer are nonendometrioid histologic 
types and are associated with increased recurrence and distant spread. 
Endometrioid type had 92 % survival rate  but patients with one of the 
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aggressive subtypes like adenosquamous, serous, clear cell  and 
undifferentiated had survival of only 33%. 
Histologic Grade 
The degree of differentiation is one of the most sensitive 
indicators to assess tumor spread. Poorly differentiated tumours(Grade 
III) are associated with deep myometrial invasion and, subsequently, 
higher rates of pelvic and paraaortic lymph node involvement . 
Myometrial Invasion 
The depth of myometrial invasion should be recorded in all 
pathologic reports, preferably in both millimeters and in the 
percentage of total myometrial thickness. Deep myometrial invasion 
increases the access of tumour to lymphatic system and is associated 
with a increased extrauterine tumor spread, treatment failure, and 
recurrence. 
Isthmus-Cervix Extension 
The position of tumor within the uterus has generally been 
considered to be important in the prediction of nodal spread. If only 
the fundus is involved, 8% of patients may have pelvic node 
metastases. Isthmus-cervix (lower segment) involement is associated 
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with 16 % risk. Fundal lesions have  4 % paraaortic lymph nodes, and  
lower-segment lesions have a 14% risk of positive paraaortic nodes . 
Vascular Space Invasion 
Lymphatic invasion is a strong predictor of tumor recurrence 
and death from tumor and is irrespective of depth of myometrial 
invasion or differentiation .It identifies patients who can have spread 
to lymph nodes especially pelvic nodes or distant sites. 
Adnexal Involvement 
Six percent of clinical stage I and occult stage II patients have 
spread of tumor to the adnexa. Of these, 32% have pelvic node 
metastases compared with 8% pelvic node positivity if adnexal 
involvement is not present. 20% have positive paraaortic node 
metastases, which is four times greater than if adnexal metastases are 
not present. 
Intraperitoneal Spread 
Intraperitoneal spread in the absence of adnexal metastases is 
associated with lymph nodes involvement. 51% percent of patients 
with  intraperitoneal spread have  pelvic node involvement. Positive 
paraaortic nodes is seen in 23% of patients with peritoneal spread.(14) 
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Peritoneal Cytology  
Positive peritoneal cytology causes decreased survival only if 
there is adnexal , peritoneal or lymph nodal involvement and not if the 
disease localised to the uterus. In the absence of other poor prognostic 
factors, positive peritoneal cytology has no significant effect on 
recurrence and survival. 
Pelvic and Paraaortic Lymph Node Metastases 
  The most significant prognostic factor affecting survival in  
early stage carcinoma is lymph node involvement. The highest rate of 
paraaortic node metastases (32%) occurred if pelvic nodes were 
involved. 5 year survival for patients with metastasis is 54 % and 90 % 
for those with absent lymph node metastases. 
Ploidy 
Glands comprised of diploid cells seen in 75% of endometrial 
tumors. Diploidy is associated with non aggressive types, < 50% 
invasion, and grade I tumors. Diploidy is associated with high survival 
rates and the differences in progression-free survival among stage I 
patients have been as great as 94% for those with diploid tumors 
versus 64% for those with aneuploid  cancers .  
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Steroid Receptors 
Geisinger et al. noted that both ER and PR positivity is 
associated with better survival. Ehrlich et al., noted absence of ERs or 
PRs, causes decreased recurrence and better response to progesterone 
treatment. In contrast, assessment of steroid receptors in metastases 
may be helpful in the decision about appropriate therapy for recurrent 
tumors. 
MOLECULAR ALTERATIONS IN THE PATHOGENESIS 
AND PROGRESSION OF ENDOMETRIAL ADENO  
CARCINOMA 
The PTEN gene is located on chromosome 10q23.Deletions or 
mutations of the PTEN gene, and microsatellite instability (MSI) due 
to hypermethylation of the promoter for the mismatch repair gene, 
hMLH1, are both relatively common and  occurs  in 30% to 50% of 
endometrial carcinoma tumors  which make this the most frequent 
genetic alteration known in this disease.(16,17,18) 
Mutations in the p53 gene are found with high frequency not 
only in invasive serous carcinoma but also in endometrial 
intraepithelial carcinoma, the noninvasive precursor of serous 
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carcinoma, suggesting that a different pathway is followed in the 
development of the second type of endometrial adenocarcinoma.  
Mutations of the p53 gene often appears to be an early event in the 
development of serous carcinoma, but it is a late event in endometrioid 
carcinomas for which it serves as an indicator of poor prognosis. (26) 
Overexpression of HER-2/neu a proto-oncogene is associated 
with poor prognosis. Nonendometrioid endometrial cancer showed a 
greater reduction in E-cadherin expression, upregulation of P-cadherin 
than endometrial cancers. Mutations in the K-ras oncogene have been 
reported in endometrioid cancer and also in endometrial hyperplasia, 
suggesting that K-ras activation may be an early event in the 
development of endometrioid carcinoma(24,25). 
PRETREATMENT EVALUATION 
After establishing diagnosis of endometrial carcinoma the 
patient should undergo a thorough evaluation. Physical examination is 
done to diagnose enlarged inguinal or supraclavicular lymph nodes, 
abdominal mass and areas of cancer spread to other pelvic organs. A 
chest radiograph is done to exclude metastasis and to evaluate the 
cardiopulmonary status of the patient. Other investigations like 
colonoscopy, cystoscopy, intravenous pyelography, and barium enema 
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is done if indicated by symptoms, on physical examination or by 
laboratory investigations. USG and MRI are used to diagnose 
myometrial invasion with several reports indicating a 75% to 90% 
accuracy rate. The only way to accurately diagnose the extent and 
depth of intrauterine invasion is by histologic examination of the 
hysterectomy specimen. 
Serum levels of the antigenic determinant CA-125 is increased 
in case of distant metastatic cancer or advanced endometrial 
carcinoma . This observation was first reported by Niloff and others  
in 1984. Values exceeding 35 U/ml were found in stage IV or 
recurrent disease, although none with stage I disease had elevations .  
Mutivariate analysis showed lymph node metastasis had the most 
significant effect on the elevation of CA-125 levels (>40 U/mL). The 
sensitivity and specificity for screening lymph node metastasis were 
78% and 84%, respectively. Hsieh et al.'s(15) data give evidence that 
preoperative CA-125 levels greater than 40 U/mL can be considered 
an indication for full pelvic and para -aortic lymphadenectomy in the 
surgical staging of endometrial carcinoma. If the initial value of CA-
125 is elevated, serial measurements may help indicate response to 
tumor therapy. 
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Surgical Technique 
Operative procedure is by midline vertical incision and 
followed by peritoneal fluid cytology, thorough exploration of intra-
abdominal and pelvic organs, with excision or biopsy of any 
suspicious lesion. Uterus should be examined for serosal invasion.  
Total abdominal hysterectomy with Bilateral salpingo-oopherectomy 
is the primary surgery for endometrial carcinoma. . The plane of 
excision lies outside the pubocervical fascia and does not require 
unroofing of the ureters. The ovarian and fallopian tubes are removed 
en bloc with the uterus. Invasion of the myometrium may be more 
extensive microscopically than is evident visibly because of the 
characteristic infiltrative growth pattern of the tumor, although gross 
visual examination by the operating team of the cut uterine surface at 
the tumor site can accurately determine the depth of myometrial 
invasion in 91% of the patients. 
Minimally Invasive Procedures 
Laparoscopic lymph node dissection along with total 
laparoscopic hysterectomy is being used in many practices. Phase III 
trial evaluated laparoscopy for comprehensive surgical staging.  
Results indicate that 26% of patients needed conversion to laparotomy 
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because of poor visibility, metastatic cancer, bleeding, increased age, 
or increased body mass index. Significantly fewer postoperative 
adverse events and shorter hospitalization occurred with laparoscopy 
compared with laparotomy. However, laparotomy may still be 
required for certain clinical situations (such as elderly patients, those 
with a very large uterus) or certain   metastatic presentations. 
  Robotic surgery is a new minimally invasive technology that 
has been advocated by some as being a feasible approach in the 
primary management of endometrial cancer. Costs for equipment and 
maintenance remain high.  
Indications for retroperitoneal node sampling 
 Myometrial invasion more than 50% 
 Isthmus-cervix extension 
 Extrauterine spread 
 Serous, clear-cell, squamous, or undifferentiated cell types 
 Enlarged lymph nodes 
 Grade III tumours 
Lymph nodes need not be sampled for tumors limited to the 
endometrium, regardless of grade, because less than 1% of these 
patients have disease spread to pelvic or paraaortic lymph nodes. 
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Mayo criteria for omission of lymphadenectomy in surgical 
management of endometrial cancer. 
Omit lymphadenectomy if no disease beyond the uterine corpus 
And (1) Endometroid grade 1 or 2, myometrial invasion ≤50%, and 
tumor diameter ≤2 cm Or (2) Endometroid and no myometrial 
invasion independent of grade and tumor diameter. 
 When indicated paraaortic nodal dissection is done through 
midline peritoneal incision over aorta and common iliac arteries. In 
some cases, pelvic lymph node sampling is indicated. Samples are 
taken from the distal common iliac nodes and from the superior iliac 
nodes. Another sample is taken from the obturator group of lymph 
nodes. Then the patient is staged according to the 2008 FIGO criteria.  
                                                                                            
 
 
 
 
Specimen of Surgical Staging showing TAH with BSO & bilateral 
lymphadenectomy 
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Primary Treatment  
NCCN guidelines divides pure endometrioid carcinoma into the 
following categories: 
 1) Disease confined to the uterus, 
 2) Suspected or gross cervix involvement 
 3) Suspected extrauterine disease 
 Disease Limited To The Uterus (Stage I) 
Most patients present with stage I disease and surgery with/ 
without adjuvant therapy is recommended for patients who are 
medically operable.  
Medically Operable Patients 
For the staging of a patient (if medically operable) with 
endometrioid histologies clinically confined to the fundal portion of 
the uterus, the recommended surgical procedure includes peritoneal 
lavage for cytology and total hysterectomy/ bilateral salpingo-
oophorectomy (TH/BSO) with dissection of pelvic and para-aortic 
lymph nodes . 
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NCCN  recommends complete surgical staging for all patients if 
they do not have medical contraindications to nodal dissection . 
Lymphadenectomy identifies those with nodal metastases to guide 
appropriate adjuvant treatment with RT and / or chemotherapy   to 
improve survival .  
Although all endometrial cancers are treated with hysterectomy, 
hormone therapy is considered for selected patients like.  
1) Young women desiring fertility with atypical endometrial 
hyperplasia or grade 1 hyperplasia 
2) Women who are poor candidates for surgery. 
These patients have to be closely monitored by endometrial 
biopsies every 3-6 months.  
Medically Inoperable Patients 
For patients who are medically unfit for surgery tumor-directed 
RT is recommended. Hormonal therapy is given for patients with 
estrogen and progesterone receptor–positive status and if they are not 
candidates for RT or surgery. These patients are closely monitored 
with endometrial biopsies every 3-6 months. Medroxyprogesterone 
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acetate is used and has low toxicity. Tamoxifen and aromatase 
inhibitors have also been used.  
Suspected or Gross Cervical Involvement (STAGE II) 
Patients who have suspected or gross cervix involvement cervix 
biopsy or MRI is done. If it is negative, disease is assumed to be 
limited to the uterus and are treated as STAGE I. 
Operable Stage II patients are treated with radical hysterectomy 
along with BSO, cytology (peritoneal lavage), and pelvic and para-
aortic lymph nodes dissection as it may be difficult to differentiate 
stage II endometrial cancer fom primary cervix cancer. In these 
patients, radical hysterectomy may improve local control and survival 
when compared with total hysterectomy. Alternatively, the patient 
may undergo RT followed by TH/BSO with para-aortic lymph node 
dissection. 
For patients who are medically unfit for surgery, tumor-directed 
RT controls local recurrence and improves survival. 
Adjuvant Therapy for Stage I and II 
Complete surgical staging gives information to select adjuvant 
therapy for endometrial tumors. Stage I endometrial carcinoma, who 
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are completely surgically staged are assessed by adverse risk factors 
like age, lymphovascular space invasion [LVSI], increased tumor size, 
and  spread to lower uterine [cervical/glandular] segment . 
Adjuvant RT 
Phase III trials have studied adjuvant therapy in patients with 
stage I disease. Adjuvant RT improves pelvic control in patients with  
risk factors though it did not improve overall survival. Adverse 
intrauterine pathologic risk factors include high-grade tumors, deep 
myometrial invasion and consequently more advanced stage, LVSI, 
and papillary serous or clear cell histologies. The Keys’ trial (GOG 
99) showed that adjuvant pelvic RT improved locoregional control 
and relapse-free interval (progression-free survival), without overall 
survival benefit. Both the GOG 99 and PORTEC-1 trials revealed that 
most of the initial recurrences for stage I occurred in vagina which 
lead to increased use of vaginal brachytherapy alone. PORTEC-2 
showed equal control rates with both whole pelvic RT and vaginal 
brachytherapy approaches, and there is no difference in survival. Since 
vaginal brachytherapy is associated with less toxicity, stage I disease 
is treated with brachytherapy alone.   
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Adjuvant Chemoradiation  
Patients with stage IB, grade 3 have a relatively poor prognosis. 
Despite adjuvant therapy with pelvic RT, a significant number of 
patients continue to have an appreciable risk of distant metastases.      
In these cases, progression-free survival is improved with adjuvant 
sequential chemoRT.   
` Adjuvant treatment for stage IA, IB: 
 
Adjuvant treatment for stage II, IIIA: 
41 
 
Suspected Extrauterine Disease (STAGE III AND IV) 
If extrauterine disease (endometrioid histologies) is suspected, 
imaging studies is done if indicated clinically. Patients with no 
extrauterine disease are treated as STAGE I. 
Spread of carcinoma to omentum, nodes, adnexa, or peritoneum 
is treated with surgical staging and optimal debulking. Unresectable 
disease spread to extrauterine pelvic sites like vagina, small bowel, 
rectum, bladder, or parametrium are treated with pelvicRT and 
brachytherapy with /without chemotherapy. Distant spread like liver 
involvement is treated with palliative TAH/BSO with/without 
chemotherapy, Radiotherapy, and/or hormonal therapy.  
ADJUVANT THERAPY FOR STAGE III /IV 
Spread of carcinoma to extrauterine sites is associated with 
increased risk for recurrence and hence given adjuvant therapy. Pelvic 
or extended-field RT is given to patients with spread of the disease to 
the lymph nodes or the adnexa. However, chemotherapy is regarded as 
the foundation of adjuvant therapy for patients with extrauterine 
disease. Previously, whole abdominal RT was used for carefully 
selected patients deemed at risk for peritoneal failure. 
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But GOG trial reported that AP chemotherapy improved 
progression-free survival and overall survival when compared with 
whole abdominopelvic RT; however, acute toxicity (eg, peripheral 
neuropathy) was greater in the AP chemotherapy arm. 
Incomplete Surgical Staging 
For patients with incomplete surgical staging, radiologic 
imaging is often recommended, especially in patients with higher 
grade and more deeply invasive tumors. Surgical restaging, including 
lymph node dissection, can also be done. Based on the radiologic 
and/or surgical restaging results, recommended treatment options are 
available. 
 Principles of Adjuvant Radiotherapy  
RT has been a widely used modality in the treatment of patients 
with endometrial cancer; it clearly improves locoregional control. 
Tumor-directed RT refers to RT directed at sites of known or 
suspected tumor involvement and may include external-beam RT 
and/or brachytherapy. Although adjuvant RT is typically not 
associated with high rates of severe morbidity, recent studies have 
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focused on subtle effects on quality of life (eg, diarrhea, bowel 
symptoms) that deserve further investigation. 
Principles of adjuvant Chemotherapy for Metastatic, Recurrent, 
or High-Risk Disease 
Multiagent chemotherapy regimens are preferred for metastatic, 
recurrent, or high-risk disease, if tolerated. Single-agent therapy can 
also be used. A phase III randomized trial compared 2 combination 
chemotherapy regimens in women with advanced/metastatic or 
recurrent endometrial carcinoma. The 3-drug regimen (cisplatin, 
doxorubicin, and paclitaxel) was associated with improved survival 
(15 versus 12 months, P < .04) but with significantly increased 
toxicity (ie, peripheral neuropathy).  For patients in whom paclitaxel is 
contraindicated, docetaxel can be considered in combination with 
carboplatin. If multiagent chemotherapy regimens are contraindicated, 
then single-agent therapy options include cisplatin, carboplatin, 
paclitaxel, doxorubicin, liposomal doxorubicin, and docetaxel. Some 
oncologists have used liposomal doxorubicin, because it is less toxic 
than doxorubicin; the response rate of liposomal doxorubicin is 9.5%. 
Recently, bevacizumab was shown to have a 13.5% response rate and 
overall survival rate of 10.5 months in a phase II trial for persistent or 
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recurrent endometrial cancer. The panel recommends bevacizumab as 
single-agent therapy for patients who have progressed on previous 
cytotoxic chemotherapy. 
Hormone Replacement Therapy for Hypoestrogenism 
After bilateral salpingo-oophorectomy, hypoestrogenism is 
associated with hot flushes, mood instability, osteoporosis, vaginal 
dryness, pelvic floor atrophy, and risk of cardiovascular disease.         
In postmenopausal women, hormone replacement therapy was 
believed to decrease the signs and symptoms. However, women who 
have had bilateral salpingo-oophorectomy for endometrial 
adenocarcinoma are not given hormone replacement therapy due to a 
high relpase rate . In women with stage I-II endometrial cancer who 
had hysterectomy, a randomized trial of estrogen replacement therapy 
versus placebo did not find an increased rate of recurrence or new 
malignancy. There should be a 6- to 12-month interval between  
adjuvant therapy and hormone replacement therapy. Selective 
estrogen-receptor modulators (SERMs) may prove to be attractive 
options for hormone replacement therapy.  
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Serous And Clear-Cell Histologies  
Uterine papillary serous carcinomas , clear cell carcinomas  and 
carcinosarcomas are very aggressive histologic variants of epithelial 
carcinoma, with a high incidence of spread to extrauterine sites. 
Patients may present with pelvic masses, abnormal cervical cytology, 
or ascites in addition to postmenopausal bleeding. Both the NCCN 
panel and the SGO recommend that CA 125 and MRI/CT may be 
useful before surgery to assess if extrauterine disease is present. 
Papillary serous carcinomas, clear cell carcinomas, and 
carcinosarcomas are all considered high-risk tumors (ie, grade 3), 
although they are staged using the same FIGO/AJCC staging system 
as endometrial cancers. Multimodality therapy is recommended for 
these tumors. Primary treatment includes staging laprotomy and 
maximal tumor debulking. For patients with stage IA without 
myometrial invasion, options include 1) observation; 2) 
chemotherapy; or 3) tumor-directed RT. For all other patients with 
more advanced disease, chemotherapy with (or without) tumor-
directed RT is the preferred option than RT alone. Adjuvant 
platinum/taxane-based therapy appears to improve survival in patients 
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with uterine papillary serous carcinoma and clear cell carcinoma, 
whereas ifosfamide/paclitaxel is recommended for carcinosarcomas.   
Carcinosarcomas (Malignant mixed mullerian tumours) 
Carcinosarcomas are aggressive tumors that are staged as high-
grade endometrial cancer. Pathologists now believe that 
carcinosarcomas ( MMMTs) are metaplastic carcinomas and not 
uterine sarcomas; therefore, the NCCN panel recently moved 
carcinosarcomas to the  epithelial carcinoma guideline . Ifosfamide 
was historically considered the most active single agent for 
carcinosarcoma. A phase III trial for advanced carcinosarcoma 
showed that the combination of ifosfamide and paclitaxel increased 
survival and was less toxic than the previously used 
cisplatin/ifosfamide regimen.   
Post-Treatment Surveillance 
50%-70% of patients have symptomatic recurrences within 3 
years of initial treatment. Hence surveillance is carried as follows. 
  Physical examination every 3-6 months for 2 years, then 6 
months or annually. 
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Patient has to be educated regarding symptoms. CA-125 
measurement is optional. Chest x-ray is taken annually. CT/MRI is 
done if clinically indicated. 
Consider genetic counselling/testing for young patients  
(<55years) with a significant family history and/or selected pathologic 
risk features. 
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MATERIALS AND METHODS 
The  clinicopathological study of endometrial carcinoma  was 
conducted at Institute of Obstetrics and Gynaecology, Egmore, 
Chennai. It was conducted from June 2011 to December 2013 for a 
period of 30 months .A prospective review of  62 patients who 
underwent therapy for endometrial carcinoma was conducted. 
 
INCLUSION CRITERIA 
Perimenopausal   and postmenopausal women who presented 
with clinical features , imaging features and histopathological findings 
suggestive of endometrial carcinoma registered in medical oncology 
department, Institute of Obstetrics and Gynaecology from  1.6. 2011 
to 1.6.2013 
 
EXCLUSION CRITERIA 
1. Secondary tumors of endometrium from ovary and cervix 
2. Recurrent endometrial carcinoma 
3. Endometrial carcinoma presenting as emergencies 
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METHODOLOGY 
All patients who were diagnosed to have endometrial carcinoma 
by dilatation and curettage or detected after surgery by 
histopathological examination are enrolled in the study. Their clinical 
profile was analyzed for various demographic details, presenting signs 
and symptoms, menstrual history, associated medical disorders and 
family history .Their height, weight were noted and BMI was 
calculated. Clinical examination findings and results of Pap smear,  
CA 125, USG, CT or MRI and dilatation and curettage were tabulated.  
Details of surgical procedure and intraoperative findings were 
recorded. Patients were then staged as per FIGO staging and 
histopathological features were documented. Patients were then either 
observed as in stage I A or given appropriate adjuvant therapy post 
operatively with vaginal brachytherapy or chemoradiation. for other 
stages. All patients were followed throughout the study. Data were 
entered into a standard proforma and analyzed. Survival was analysed 
using life table curves and statistical significance was tested using log 
rank test. 
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OBSERVATIONS AND RESULTS 
This descriptive study was conducted in the INSTITUTE OF 
OBSTETRICS AND GYNAECOLOGY for a period of 30 months 
among the patients who were diagnosed to have endometrial 
carcinoma. There were a total of 62 patients during the study period 
and  they were analyzed as follows. 
TABLE 1: AGE WISE DISTRIBUTION OF PATIENTS 
 
 
TABLE 2: SOCIO ECONOMIC STATUS 
 
AGE (YEARS) NO. OF CASES PERCENTAGE 
< 45 2 3.2 
45- 50 9 14.5 
50 - 55 15 24.2 
55 -60 16 25.8 
60 -65 11 17.7 
>65 9 14.5 
Total 62 100.0 
SOCIO ECONOMIC 
STATUS NO. OF CASES PERCENTAGE 
I 0 0 
II 1 1.6 
III 8 12.9 
IV 30 48.38 
V 23 37.09 
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Average age at diagnosis was  55.73 years. Minimum  age was  
40 years and  maximum was 70 years.
FIGURE 1 
This diagram illustrates that 82.2 % patients were above 50 
years of age. 
FIGURE 2 
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 TABLE 3
 
>13 years 
<13 years 
Total 
Percentage of cases who attained menarche less 
years was calculated and it accounted to about 24.2% of cases
FIGURE 3 
 
24.19 %
DISTRIBUTION OF PATIENTS AS 
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52 
 : AGE AT MENARCHE 
NO OF CASES PERCENTAGE
47 75.8 
15 24.2 
62 100.0 
than 13 
75.81 %
ABOVE 13 YRS
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 TABLE 4
 
Irregular 
Regular 
Total 
 
Among  total 62 cases , 40.3% had irregular cycles and 59.7% 
had regular cycles. 
FIGURE 4 
 
 
DISTRIBUTION OF CASES  AS PER 
53 
: MENSTRUAL CYCLES 
NO OF CASES PERCENTAGE
25 40.3 
37 59.7 
62 100.0 
IRREGULAR, 40.3
2 %
REGULAR,  59.68 
%
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 TABLE 5
 
AGE AT MENOPAUSE
<52 yrs 
> 52 yrs 
Not Attained 
Total 
Among 62 cases , 12 cases did not attain menopause. Of the 50 
cases who attained menopause, 51.6 %
years and  29.0% attained after 52 years.
FIGURE 5 
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:  AGE AT MENOPAUSE 
 NO. OF CASES PERCENTAGE
32 51.6
18 29.0
12 19.3
62 100.0
 attained at age less than 52 
 
 
 
 
 
 
 
  
 
Multiparous 
Nulliparous 
Total 
 
Among  62 cases, 53 cases were multiparous women and 9 
cases were nulliparous .
FIGURE 6 
 
NULLIPAROUS
DISTRIBUTION OF PARITY 
55 
TABLE 6: PARITY 
NO OF CASES PERCENTAGE
53 85.5 
9 14.5 
62 100 
 
 
MULTIPAROUS
 
 
 37.1 %
DISTRIBUTION OF MEDICAL DISORDER
DM HT
TABLE 7: DISTRIBUTION OF MEDICAL DISORDERS
 
MEDICAL DISORDERS
Diabetes Mellitus 
Hypertension 
Hypothyroidism 
Multiple Disorders 
No disorder 
 
 
FIGURE 7 
In this study 37.1% of cases had diabetes mellitus, 24.2% had 
hypertension and 14.5% had hypothyroidism. 12.9 % had
one of the above disorders.
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HYPOTHYROIDISM MULTIPLE DISORDER
 NO.OF CASES PERCENTAGE
23 37.1
15 24.2
9 14.5
8 12.9
26 41.1
 more than 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DISTRIBUTION OF CASES  AS PER BMI
TABLE 8 
 
 
 
BMI 
20 - 25 
26 -30 
Above 30 
Total 
 
 
FIGURE 8 
 
 
Of the 62 cases, 29 cases were overweight and 12 were obese.
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: DISTRIBUTION AS PER BMI 
 
NO. OF CASES PERCENTAGE
21 33.87 
29 46.77 
12 19.35 
62 100.0 
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TABLE 9: DISTRIBUTION OF CASES AS PER 
PRESENTING SYMPTOMS
SYMPTOM 
Post  menopausal bleeding
Peri menopausal bleeding
Vaginal discharge 
Pain 
Loss of weight /appetite 
 
Postmenopausal bleeding is the mo
56% of patients  followed by perimenopausal bleeding in 19.3% .
FIGURE 9 
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TABLE 10 : DISTRIBUTION AS PER VAGINAL 
EXAMINATION 
 
CLINICAL FINDING NO, OF CASES PERCENTAGE 
Bulky uterus 30 48.4 
Normal size 20 32.2 
More than 10 weeks size 5 8. 0 
Atrophic 3 4.8 
Size not made out 2 3.2 
Adnexal mass 2 3.2 
Total 62 100.0 
 
On vaginal examination, about 48.4 % had bulky uterus while 33.9% 
had normal sized uterus. About 4.8 % cases had atrophic uterus. Due 
to obesity exact size of uterus could not be made out in 2 cases. 
TABLE 11 : CA 125 
 
 
CA 125 NO. OF CASES PERCENTAGE 
>35 2 25 
<35 6 75 
Total 8 100 
  
CA 125 was done only in 8 cases. of the 8 , 2 cases levels > 35 U/ml 
accounting to about 25 %. remaining 6 cases (75%) had <35 U/ml. 
 TABLE 12
 
FINDING 
Negative for sil 
Inflammatory smear 
Ascus 
Total 
 
Pap smear was done for all patients except for 5 cases who had 
bleeding.  Of the 57 cases for whom Pap smear was done 47 
cases(82.4%) were negative for SIL,
inflammatory smear and 1 (1.6%) had ASCUS. 
FIGURE 10 
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 TABLE 13
 
 
FINDING 
Thickened endometrium
Fibroid  
Mass 
Normal 
Polyp 
 
 In ultrasound , thickened endometrium was found in 98.3% , fibroid 
was diagnosed in 12.9%  and  mass was detected in 8.1% of cases
FIGURE 11 
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TABLE 14: FINDINGS FROM CT 
 
  
  
FINDING NO.OF CASES PERCENTAGE 
Mass 16 50% 
Thickened endometrium 12 37.5% 
Fluid collection 3 9.37% 
Nodes 3 9.37% 
Normal  2 6.25% 
Rectal invasion 1 3.1% 
Omental deposits 1 3.1% 
 
CT scan was done in 32 cases. The most common finding was 
endometrial mass in 16 cases which is about 50 %, followed by 
thickened endometrium in about 37.5 % cases. Fluid collection was 
seen in 9.37 % of cases and nodes were diagnosed  in about 9.37% of 
cases. Rectal  invasion and omental deposits was diagnosed in one 
case each. 
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FRACTIONAL CURRETAGE
TABLE 15: DISTRIBUTION AS PER FINDINGS IN 
FRACTIONAL CURETTAGE
FINDINGS 
Endometrioid Adenocarcinoma
Villoglandular Carcinoma
Papillary Serous Carcinoma
Complex Atypical Hyperplasia
Endometrial Intraepithelial Neoplasia
Endometrial Stromal Sarcoma
Proliferative phase 
Post menopausal state 
Total 
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77.4
3.2 1.6 1.6
4.8 6.5
 
NO.OF CASES PERCENTAGE
 48 77.4 
 4 6.5 
 1 1.6 
 2 3.2 
 1 1.6 
 2 3.2 
3 4.8 
1 1.6 
62 100% 
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TAH  With BSO 
Staging laprotomy 
Not done 
Total 
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1.6%
25.8%
SURGERY
STAGING LAPROTOMY TAH BSO
SURGERY DONE 
NO. OF CASES PERCENTAGE
45 72.6 
16 25.8 
1 1.6 
62 100.0 
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TABLE 17: DISTRIBUTION OF CASES ACCORDING 
TO HISTOLOGIC TYPE 
 
HISTOLOGIC TYPE NO.OF CASES PERCENTAGE 
Endometroid Adenocarcinoma 60 96.77 
Clear Cell Carcinoma 1 1.6 
Not Available 1 1.6 
Total 62 100.0 
 
Among the 62 cases studied 60 cases were endometrioid 
adenocarcinoma accounting to 96.77% and one was  clear cell 
carcinoma type contributing to 1.6 %.  5 cases of Villoglandular 
variant contributed to 8.3 % of the total endometrioid carcinoma. One 
case had synchronous endometrioid tumour of ovary and uterus  and 
another patient had incidental thecoma of ovary. 
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TABLE 18: DISTRIBUTION OF CASES AS PER 
GRADE OF TUMOUR
 
 
Of the 62 cases, 36 were of grade I which  is about 58.1 %, 15 
cases were grade II accounting to about 24.1% and 10 were Grade III 
which is about 16.1%
FIGURE 17 
GRADE NO.OF CASES
I 
II 
III 
Not Available 
Total 
68 
II III NA
 
 
. 
 
 PERCENTAGE
36 58.1 
15 24.1 
10 16.1 
1 1.6 
62 100.0 
 
 TABLE 19: DISTRIBUTION AS PER 
MYOMETRIAL 
 
DEPTH OF MYOMETRIAL 
INVASION
<50 %
>50 %
Total
55.73% of cases in our study had <50% Myometrial Invasion while 
44.26% had >50% Myometrial Invasion.
FIGURE 18 
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DEPTH OF 
INVASION 
 
NO.OF 
CASES PERCENTAGE
 
34 55.73
 
27 44.26
 
61 100
 
 
55.73
 
 
 
 
 
<50
>50
 TABLE 20: DISTRIBUTION OF SITES 
SITE OF EXTRAUTERINE SPREAD
Nodes 
Adnexa 
Omental deposits 
Cervix 
Positive peritoneal cytology
Rectal invasion 
Serosal invasion 
 
          Among extrauterine spread nodes contributed 
adnexa, omentum and cervix were involved in 16.6% each.
FIGURE 19 
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TABLE 21 : DISTRIBUTION OF CASES AS PER FIGO 
STAGE 
I A 
IB 
II 
IIIA 
III B 
III C 
IV A 
IV B 
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II IIIA III B III C IV A IV B
STAGE 
FREQUENCY PERCENTAGE
35 56.4 
16 25.8 
2 3.2 
2 3.2 
0 0 
3 4.8 
1 1.6 
2 3.2 
I A
IB
II
IIIA
III B
III C
IV A
IV B
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DISCUSSION 
Age 
Minimum age of endometrial carcinoma reported in the present 
study was 40 years and maximum was 70 years.  The average age of 
occurrence of endometrial carcinoma is 55.73 years. This is very close 
to the average age reported by various authors  that is 60 years. Indeed 
it occurs at a younger age in our population. 
Various studies have shown that 75% to 80 % of cases occur in 
women older than 50 years. In our study too, about 82.2 % of cases 
are above 50 years. 
Socioeconomic Status 
 Endometrial carcinoma is thought to be prevalent in higher 
socioeconomic status in the Western countries. But in our study about 
49 % of the patients belonged to class IV and 38% belonged to classV. 
Hence endometrial carcinoma is no longer a disease of affluent people 
in our population. 
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ANALYSIS OF RISK FACTORS 
Age At Menarche 
Early menarche (at age less than 13 years) has 1.5 to 2 times 
risk of endometrial carcinoma. In the present study, only 24.2% of 
cases attained early menarche. 
Menstrual Cycles 
 Hyperoestrogenism  due to  anovulatory cycles  causes 
menstrual irregularity and infertility  poses 1.5 to 3 times risk of  
uterine carcinoma. Menstrual irregularity was elicited in about 40.3 % 
of   our patients. 
Age At Menopause 
MacMahon et al elicited that late menopause occurring after the 
age of 52 years increases the risk of endometrial carcinoma and they 
are 2 to 3 times likely to get the disease. Hence when we analyzed the 
age of menopause in our patients, it is seen that 12 cases did not attain 
menopause, and all of them were less than 50 years. Of the 50 cases 
who attained menopause, 51.6 % attained at age less than 52 years and  
only  29 % attained after 52 years. 
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Parity 
Nulliparity due to prolonged period of exposure to oestrogen is 
a proven risk factor for endometrial cancer with a relative risk of   2 to 
3. Moreover, a woman’s endometrial cancer risk decreases with each 
child birth. Jabo et al in his study observed  that nulliparity was found 
only in 19.9 % of patients . In the present study about 14.5 % were 
nulliparous women and remaining 85.5 % were multiparous . 
Medical Disorders 
Diabetes mellitus increases a women’s risk for endometrial 
cancer by 1.3 to 2.8 times. Richard Barakat observed that especially 
Type II diabetes associated with insulin resistance and 
hyperinsulinemia is associated with higher risk. Additionally, there is 
evidence that obese diabetic women have the highest risk of 
developing disease. 
In our study, 23 out of 62 patients had diabetes mellitus         
(37 .1 %). Also, of the 23 cases with diabetes, 19 were Type II DM. 
Hypertension increases the risk by 1.5 times. In the present study 
about 24.2% cases had associated hypertension. In various studies, 
Hypothyroidism is found to be associated with endometrial carcinoma 
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but exact causal relationship is yet to be established. In our group of 
patients, 9 cases contributing to about 14.5 % had history of 
hypothyroidism. One patient had associated ischemic heart disease. Of 
these cases with associated medical disorders, 8 cases had more than 
one of the above disorders. 
Obesity 
Obesity is an undisputed risk factor for endometrial carcinoma 
as it increases oestrogen levels by increased peripheral aromatization 
of androstenedione.   Bereck and Novak ‘s states that 21 to 50 pounds 
( 9 to 22 kg) overweight increases risk for endometrial cancer by 3 
times and  more than 50 pounds (22 kg) above average weight 
increases risk by 10 times.  
 In a study on epidemiology conducted by Karen et al, obesity a 
risk factor for endometrial cancer and has been reported to account for 
17–46% of all cases. They also found that overweight women had 
twice the risk of developing disease as normal-weight women, while 
in obese women the risk is four to five times. Brinton et al. reported 
that women with a body mass index (BMI) of 32 kg/m2 or greater 
were four times as likely to develop endometrial cancer as women 
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with a BMI of less than 23 kg/m2, while women with a BMI of 35 
kg/m2 or greater had six times the risk. Additionally, there are some 
data to suggest that for each 5 kg/m2 increase in BMI, there is a 
significant increase in risk of developing endometrial cancer. Iatrakis 
et al found that there was strong relationship between increased BMI 
and endometrial carcinoma. 
Obesity in our study group was analyzed using Body Mass 
Index (BMI). It is observed that about 66.12 % (41 out of 62) of the 
cases were above average body weight. Of these 46.77 % were 
overweight with BMI of 25 to 30 kg /m 2 and 19.35 % were obese 
with BMI of >30 kg/ m 2. Of these two patients were very obese with 
BMI of 37 and 39 kg/m 2. 
In our study, though the obvious causes of prolonged 
unopposed oestrogen stimulation of endometrium like early menarche, 
late menopause, irregular menstrual cycles and nulliparity were 
observed in less percentage of cases, obesity is observed in significant 
percentage (66 %) of cases. Hence increased incidence of obesity is 
the probable reason for increasing incidence of endometrial carcinoma 
in our population. 
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Other Risk Factors 
LYNCH II syndrome (previously called Hereditary 
Nonpolyposis Colorectal Cancer HNPCC) due to genetic mutation in 
mismatch repair genes increases the risk for endometrial cancer by 20 
folds. LYNCH syndrome was not observed in the present group of 
patients or in their family members. 
Post menopausal hormone replacement therapy without 
progestins increases 4 to 8 times the risk. None of the patients in our 
study had history of hormone replacement therapy. 
Tamoxifen therapy for treatment of breast cancer is associated 
with two to three fold increased risk for endometrial carcinoma. There 
was no history of Tamoxifen therapy in our study group. This is 
probably due to the small number of patients in the index study. 
PRESENTING SYMPTOM 
Novak’s reports that 90% of women with endometrial 
carcinoma have vaginal bleeding or discharge as their only symptom. 
Barakat observed that 90 % of patients have bleeding and 10% have 
vaginal discharge. In our study, main symptom was postmenopausal 
bleeding in 56 % of cases, whereas 19.3% of patients presented with 
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perimenopausal bleeding. 27.4% had vaginal discharge as their major 
complaint and 20.9 % complained of pain . Though abnormal bleeding 
was not present in 90 % of patients, it was the first major presenting 
symptom in our study group too, accounting for about 75 .3% 
CLINICAL EXAMINATION 
Vaginal examination revealed bulky uterus in about 48.4 % 
cases .Uterus was normal in size in 32.2 % and even atrophic in 4.8 % 
cases. Uterus was enlarged to more than 10 weeks size in about 8 % 
cases. Due to obesity exact size of uterus could not made out in about 
3.2 % cases. This observation shows that uterus may not be enlarged 
in all cases and that clinical examination alone may miss endometrial 
carcinoma if the uterus is of normal size or atrophic. Adnexal mass 
was identified in 2 cases which ultimately turned out to be 
synchronous ovarian tumour in one case and ovarian metastasis in 
another case. 
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INVESTIGATIONS 
Pap Smear 
Novak and Williams observe that Pap test is not a sensitive tool 
to diagnose endometrial cancer and only 30 to 50 % may have 
abnormal smear. In the present study, Pap smear was done for all 
patients except for 5 who had excessive bleeding. Of the 57 cases for 
whom Pap smear was done, 82.4 % were Negative for SIL, 15.7% had 
inflammatory smear and only one case  (1.6%) had ASCUS which was 
proved to be chronic cervicitis in cervix biopsy. None of them were 
positive for endometrial carcinoma .Hence is not a reliable tool to 
diagnose endometrial carcinoma.  
CA 125 
Serum CA 125 is the important tumour marker which is 
elevated in advanced epithelial ovarian tumours. Novak observes that 
it may be elevated in advanced endometrial carcinoma also. 
In our study serum CA 125 levels were measured in 8 cases. Of 
the 8 cases, 2 (25%) had levels > 35IU/ml and both them ovarian 
involvement at laprotomy. Remaining 6 (75%) cases had levels 
<35IU/ml , but three of them had advanced disease. Hence sensitivity 
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of serum CA 125 to diagnose advanced endometrial cancer is 40 % 
and specificity is about 75 %. 
ULTRASOUND 
Ultrasonogram is a useful adjunct to endometrial biopsy in 
evaluating postmenopausal bleeding and selecting patients for 
additional testing. ACOG in 2009 stated that in postmenopausal 
women with bleeding, endometrial stripe thickness measurement less 
than 5 mm can be attributed to endometrial atrophy. 
In the present study group, about 98.3 % cases had thickened 
endometrium (>5 mm) .Hence endometrial thickness > 5mm has high 
sensitivity in diagnosing endometrial cancer. Other findings include 
fibroid in 12.9%, mass in 8.1 %, polyp in 1.6 % of cases. Ultrasound 
was normal in 1.6 % of cases. 
COMPUTED TOMOGRAPHY (CT) 
CT scan is usually done in selected cases for further evaluation 
in endometrial carcinoma. It gives information about nodal 
involvement. In the study group CT was done for 32 cases .The most 
common finding was endometrial mass in 16 cases which is about 
50%, followed by thickened endometrium in about 37.5 % cases. 
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Fluid collection was seen in 9.37 % of cases and nodes were 
diagnosed in about 9.37% of cases. Rectal invasion and omental 
deposits were diagnosed in one case each. The sensitivity of CT to 
diagnose nodal involvement is 62 % and specificity is 96.6%. 
MRI 
MRI is not routinely done for all patients.  In the present study 
it was done for 6 patients and findings were thickened endometrium 
with polypoidal mass, omental nodules and nodal involvement.  It was 
very precise in diagnosing myometrial invasion by observing the 
endometrial myometrial interface. 
DILATION AND CURETTAGE 
 The standard method of assessing uterine bleeding and 
diagnosing endometrial carcinoma is the Dilatation and Curettage. In 
the index study, dilatation and curettage diagnosed 85.5 % of 
endometrial carcinoma, of which 77.4% were correctly diagnosed as 
endometrioid carcinoma, 6.5 % as villoglandular type and 1.6 % as 
papillary serous carcinoma. About 3.2 % of the carcinoma was falsely 
diagnosed as sarcoma and another 4.8 % of carcinoma was 
misdiagnosed as atypical hyperplasia and intraepithelial neoplasia. 
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Normal findings such as proliferative phase of menstrual cycle and 
postmenopausal state was falsely diagnosed in about 6.4 % of patients 
with endometrial carcinoma. The sensitivity of dilatation and curettage 
to diagnose endometrial is 88.70%  and  false negative  rate of 
11.29%.         
SURGERY 
Primary surgery was performed in all cases diagnosed to have 
endometrial carcinoma except one case which had rectal invasion 
diagnosed by CT scan. Total abdominal hysterectomy and bilateral 
salpingo-oopherectomy was done 72.6 % (45) of cases. For 16 cases 
(25.8%) staging laprotomy with lymph node dissection was done as 
indicated by features such as myometrial invasion >50 % by the 
tumour , isthumus or cervix extension , extrauterine spread, 
nonendometrioid histologic types or poorly differentiated tumours. 
HISTOLOGIC TYPE 
 As observed by Novak’s, Barakat and several other studies, 
endometrioid type accounts for about 80 % of endometrial carcinoma. 
In our study too, endometrioid contributed to about 96.77% of cases 
and thus the most common histologic type . Several variants are found 
in endometrioid carcinoma and endometrioid with squamous 
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differentiation, villoglandular type and secretory carcinoma. Literature 
documents squamous differention  to be the most common variant 
with incidence of 15 to 25 % of endometrioid carcinoma followed by 
villoglandular with 2 % incidence and secretory carcinoma 
contributing about 1 %.The common variant found in the index study 
is 5 cases of villoglandular carcinoma accounting for about 8.33% of 
endometrioid carcinoma. Squamous differentiation and secretory type 
was not found in our observation. 
Nonendometrioid types include mucinous carcinoma (5%), 
papillary serous carcinoma (3 – 4 %), clear cell carcinoma ( 5%) and 
undifferentiated type. The only nonendometrioid type that was 
observed was one case of clear cell carcinoma accounting for about 
1.6% of all endometrial carcinoma. 
Synchronous endometrial and ovarian cancers are the most 
frequent simultaneously occurring genital malignancies with incidence 
of 1.4 to 3.8 %. One such case of simultaneous ovarian and 
endometrial carcinoma was found in our study accounting for about 
1.6 %. It was a primary ovarian endometrioid adenocarcinoma of well 
differentiated type with poorly differentiated endometrioid 
adenocarcinoma of uterus. 
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One patient had incidental thecoma of the ovary which had been 
diagnosed due to the endometrial carcinoma. 
GRADE OF DIFFERENTIATION AND DEPTH OF 
MYOMETRIAL INVASION 
Based on degree of differentiation, FIGO has classified tumours  
into three grades. Most of the cases in our study group were Grade I    
(well differentiated) tumours with incidence of 58.1% followed by 
24.1 % of Grade II (moderately differentiated) and 16.1 % of Grade III 
(poorly differentiated )tumours . 
Invasion of the tumour into <50 % or >50 % of myometrium 
has prognostic significance. Noninvasive or Superficially invasive 
tumours have 5 year survival of 80 to 90 % while deeply invasive 
tumours have 60 % survival. Of the 62 cases studied 55.73% had 
myometrial invasion of less than <50% and   44.26 % had invasion 
>50% of myometrium.  
EXTRAUTERINE SPREAD 
Spread of tumour to extrauterine sites like serosa , adnexa , 
peritoneum, adjacent organs and lymph nodes are associated with poor 
prognosis. Lymph nodes were involved in 4.8 % of cases. Adnexa , 
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omentum and cervix was involved in 3.2 % of cases  each. Serosa was 
breached in one case and rectum involved in one case. Peritoneal 
cytology was positive for malignant cells in one case. 
FIGO STAGING 
FIGO stage of the tumour is the most significant variable 
affecting survival in endometrial carcinoma.  5- year survival for stage 
I is 87% ,  stage II is 76 %, stage III is 59% and stage IV is 18 %. 
 Of the 62 patients analyzed in our study, about 81.2 % were 
stage I with 56.4 % in stage I A and 25.8 % in stage I B. There were 
two patients with stage II contributing to about 3.2%. Of the 8 % in 
stage II, 3.2% belonged to stage IIIA (serosal and adnexal 
involvement ) and  the remaining 4.8 %   belonged to stage IIIC (nodal 
involvement ). 
ADJUVANT TREATMENT 
Stage I A was not given any adjuvant treatment and was 
observed whereas stage IB was given adjuvant RT to prevent local 
recurrences. Stage II and III was given adjuvant chemotherapy with 3 
cycles and radiotherapy while stage IV was given systemic 
chemotherapy with 6 cycles and radiotherapy  
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SURVIVAL ANALYSIS 
Interval 
Start 
Time 
Number 
Entering 
Interval 
Number of 
Terminal 
Events 
Cumulative 
Proportion 
Surviving at 
End of 
Interval 
Std. Error of 
Cumulative 
Proportion 
Surviving at 
End of 
Interval 
Hazard 
Rate 
Std. 
Error of 
Hazard 
Rate 
0 61 0 1.00 1.00 .00 .00 
2 61 0 1.00 1.41 .00 .00 
4 61 0 1.00 1.73 .00 .00 
6 61 0 1.00 2.00 .00 .00 
8 51 1 .98 2.19 .01 .01 
10 45 0 .98 2.39 .00 .00 
12 41 0 .98 2.58 .00 .00 
14 38 1 .95 2.68 .01 .01 
16 35 1 .93 2.76 .01 .01 
18 33 1 .89 2.81 .02 .02 
20 27 0 .89 2.94 .00 .00 
22 21 1 .85 2.91 .03 .03 
24 17 0 .85 3.03 .00 .00 
26 12 1 .77 2.83 .05 .05 
28 8 1 .61 2.33 .11 .11 
30 1 0 .61 2.40 .00 .00 
 
Survival of our  62 patients with endometrial carcinoma was 
analysed using  life table . It revealed the 2 year survival rate of our 
patients was 85%. It is seen that the median survival period in our 
group was 30 months. The maximum hazard rate (ie death) is 11% and 
it has occurred after 28 months of survival . 
  
 FIGURE 21 
This curve depicts the overall survival of the patients with 
endometrial carcinoma in our study 
months. Due to small number of patients in the study 
of the patients in the individual stage could not be
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group. The median survival is 30
group, survival 
 analyzed. 
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ANALYSIS OF INFLUENCE OF PROGNOSTIC FACTORS ON 
THE SURVIVAL 
S. 
NO VARIABLE  
MEDIAN 
SURVIVAL 
(MONTHS) 
P VALUE 
1 Histologic Type 
Endometrioid 30.000 
0.669 
Non Endometrioid 27.000 
2 Histologic Grade 
I 30.000 
0.267 II 26.000 
III 28.0000 
3 Myometrial Invasion 
<50% 30.000 
0.149 
>50% 27.229 
4 
 
Extrauterine 
Spread 
Absent 30.000 0.306 
 Present 26.882 
5 FIGO Stage 
I 30.000 
0.000 
II 18.000 
III 26.500 
IV 9.000 
 
The influence of various prognostic factors on survival was 
studied using lifetable analysis and significance was tested using log 
rank test. 
Studies have proved that endometrioid type is associated with 
92 % survival rate and other aggressive non endometrioid type is 
associated with 33 % survival rate. In the present study group , 
endometrioid type is associated with 30 months survival while non 
endometrioid is associated with 27 months survival. Thus survival is 
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definitely reduced with nonendometrioid aggressive types compared 
to endometrioid type. 
Novak ‘s reports  92 % and 86 % disease free 5-year survival 
for grade I and II respectively whereas 64% for grade III tumours. In 
the present study, grade I tumours had 30 months survival whereas 
grade II and III had 26 months survival each. Hence survival is 
reduced with poorly differentiated tumours when compared to well 
differentiated tumours . 
Superficially invasive tumours have survival of 80 to 90 % 
while deeply invasive tumour have survival of about 60 %. The 
present study found survival of 30 months for <50 % myometrial 
invasion and 27 months when myometrial invasion was  >50 %. 
It is proved that spread of tumour to extrauterine sites like 
omentum , adnexa , lymph nodes ,peritoneum and cervix  is associated 
with poor survival. In the index study, patients with tumour confined 
to uterus had 30 months survival while extrauterine spread had 26 
months survival. 
Though the association of factors like nonendometrioid type , 
poorly differentiated, deeply invasive tumours and extrauterine spread  
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with poor survival are not statistically significant ,these are obviously 
associated with reduced survival. The statistical insignificance can be 
attributed to small number of patients in the study group . 
The most important factor affecting prognosis is FIGO stage. 
Survival for stage I is 87%, stage II is 76%, stage III is 59 % and for 
stage IV is 18 %. When survival was analysed for our patients by 
lifetable analysis , it revealed that survival was 30 months for stage I , 
18 months for stage II , 26.5 months for stage III and  9 months  for 
stage IV. Since there was no death reported  in our patients with stage 
II disease it was excluded from log rank test and significance was 
tested for difference in survival between stage I , III and IV. The         
p value was 0.000 which is <0.05 and hence statistically significant. 
This implies that stage III has significantly increased survival than 
stage IV and stage I has the best survival. 
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SUMMARY 
This study was conducted at The Institute of Obstetrics and 
Gynaecology ,  Egmore ,Chennai from June 2011 to December 2013 
and 62 cases of endometrial carcinoma . 
The study revealed the following : 
• The average age of incidence is 55.73 years. 
• 82.2 % patients were above 50 years of age. 
• 24.2% patients  in  study group attained menarche at an early 
age. 
• 40.3% of the cases had irregular menstrual periods. 
• 12 cases did not attained menopause and 29 % of the cases 
attained late menopause . 
• Only 14.5 % patients were nulliparous. 
• 37.1% patients had diabetes mellitus, 24.2% had hypertension , 
14.5% had hypothyroidism and 12.9 % of cases had more than 
one of the above medical disorders. 
• 33.87 % had normal BMI. 
• 46.77% were overweight with BMI  of  25 to 30 kg/m2 and 
19.35 %  were  obese with BMI of  >30 kg/m2 
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• About 65 % of the patients had abnormal bleeding as the 
presenting symptom with 56 % of patients had postmenopausal 
bleeding and 19.3 % had perimenopausal bleeding. Vaginal 
discharge was the next common symptom in 27.4% of patients. 
• 48.4 % had bulky uterus on vaginal examination and uterus was 
normal in 33.9% of the cases. 
• The sensitivity of serum CA 125 to diagnose advanced 
endometrial cancer is 40 % and specificity is 75%. 
• About 95. 3 % of the patients had thickened endometrium in 
ultrasound . 
• Sensitivity of CT scan to diagnose  nodal involvement is 62 %  
and specificity is 96.6%. 
• Sensitivity of dilatation and curettage to diagnose endometrial 
carcinoma is 88.7% and false positive rate is only 11.29 %. 
• Endometrioid adenocarcinoma is the most common histologic 
type of about 96.77 % with villoglandular  variant  found in 
8.33%. One case of nonendometrioid type (clear cell 
carcinoma) was seen. One case of synchronous endometrioid 
adenocarcinoma of ovary and uterus was diagnosed. Another 
case had incidental Thecoma of ovary. 
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• 58 % had grade I tumours, 24 % had grade II and 16 % had 
grade III tumours. 
• Myometrial invasion more than 50 % was found in 24.26 % of 
the cases. 
• Extrauterine spread was present in 19.35 % of the cases. Lymph 
nodes metastasis was found in 3 cases. Tumour had spread to 
adnexa , omentum and cervix in 2 cases each. One patient had 
rectal invasion and one had serosal invasion. 
• 82.2% of the cases were FIGO stage I, 3.2% were stage II, 7 % 
were stage III and 4.8 % belonged to stage IV. 
• The overall 2- year survival rate for endometrial carcinoma in 
our group of patients was 85 %. 
• In the present study, median survival was 30 months. 
• Poor prognostic factors like nonendometrioid type of 
carcinoma, myometrial invasion , poorly differentiated tumours 
and extrauterine spread of  tumours had decreased median 
survival . 
• Stage I had best survival  and stage III had better survival than 
stage IV and this was statistically significant. 
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CONCLUSION 
The incidence of  Endometrial carcinoma is increasing in our 
country in recent years due to 
1. Increased longevity of women 
2. Increased obesity 
3. Increased incidence of Diabetes Mellitus. 
4. Westernisation  of  lifestyle. 
Early diagnosis of endometrial carcinoma is important as the 
disease is almost curable when the disease is confined to uterus. 
Increase the awareness among perimenopausal and post 
menopausal women to seek medical care immediately in case of any 
abnormal bleeding or vaginal discharge. 
Encourage healthy lifestyle and eating habits to decrease 
incidence of obesity among general population. 
Patients with intact uterus should never be prescribed oestrogen 
alone for hormone replacement therapy.It should always be combined 
with progesterone to decrease the risk of endometrial carcinoma. 
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Drugs like Selective Estrogen Receptor Modulators can also be 
used for hormone replacement therapy to avoid endometrial 
stimulation. 
Adjuvant treatment with chemotherapy and radiotherapy in high 
risk cases increases the survival. 
Multidisciplinary team approach by Gynaecologist, Surgical 
oncologist, Medical oncologist and Radiation oncologist will help to 
improve  the survival of patients with endometrial carcinoma.
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PROFORMA 
Introduction 
• Name of patient                                                           wcc no: 
• Age of patient 
• occupation 
Presenting Complaint 
History of Presenting Complaint 
• Menstrual problems / Irregular bleeding 
• Duration of problem 
• Cycle length 
• Length of period 
• How heavy is each period 
• Tampons or pads - how many a day / or both at once 
• Clots 
• Flooding 
• Intermenstrual bleeding 
• Post coital bleeding 
• Pain with period 
• Any previous treatment 
• Any previous investigations 
• Ever miss work/ school for problem 
• Ever been anaemic 
   Unusual vaginal discharge 
• foul smelling 
• pus-like 
• blood tinged 
    Pelvic pain 
• If pain is involved ascertain site, radiation (if any) and character 
• Onset 
• Periodicity 
• Duration 
• Recurrence? 
• Aggravating & relieving factors 
• Severity 
• Previous sexually transmitted infections 
• Dyspareunia – deep or superficial 
• Post-coital bleeding 
  
    Change in bladder habits 
• pain during urination 
• difficult urination 
• blood in the urine 
      Change in bowel habits 
• pain during bowel movement 
• difficult bowel movement 
• blood in the stool 
• ascites (buildup of fluid in the abdomen), which causes abdominal 
swelling 
• weight loss 
• loss of apetite 
       Menstrual History 
• Menarche and menopause 
• 1st day of last menstrual period 
• Length of bleeding (days) 
• Frequency 
• Regularity 
• Bleeding between periods 
• Bleeding after intercourse 
Any post menopausal bleeding *Nature of periods 
• Heavy? 
• Clots? 
• Flooding? 
Past Gynecological History 
• Gynecological symptoms 
• Gynecological diagnoses 
• Gynecological surgery 
• h/o endometrial hyperplasia 
• Date & result of cervical smears 
• Contraception 
  
  
Past Obstetric History 
o Gravidity and Parity 
• Induction of labor/Spontaneous 
• Normal Delivery/casearean 
• Weight of babies 
• Sex of babies 
• Complications before, during and after delivery 
o  Any terminations 
o  Any miscarriages 
o  Any ectopic pregnancies 
 
    Drug History 
• Prescribed medications 
• use of tamoxifen for breast cancer 
• Any known drug allergies . 
• Any tablets / inhalers 
• Allergies 
 
  Past Medical History 
• Past operations 
• diabetes  
• hypertension 
•  Other medical conditions 
• Current or past illnesses 
• Hospital admissions 
• Past surgeries 
 Family History 
• Family history of hypertension, diabetes 
• Family history of breast lumps / cancer / other gynaecological 
cancers 
Personal History 
• estrogen replacement therapy 
• smoking 
• alcohol 
 Smear History 
•  When last smear 
•  Always normal? 
•  Any previous problems 
•  Ever had a colposcopy? 
  
 
General Examination: 
• Ht           
•  Wt             
• BSA 
•  BMI 
• Pulse 
• Blood Pressure  
• Respiratory Rate  
• Temperature 
• Anaemia  
• Cyanosis  
• Jaundice 
 
Systemic examination: 
 
CVS: 
 RS: 
CNS: 
ABD : 
          PER VAGINAL EXAMINATION: 
Investigations 
 
o Complete blood count   N/ABN  
o  Blood chemistry tests 
o LFT  N/ABN     
o Tumour marker tests 
o Transvaginal ultrasound 
o  Endometrial Biopsy 
o Dilatation and curettage 
o Endoscopy 
 Hysteroscopy 
 Cystoscopy 
 Proctoscopy 
o Chest x-ray 
o Computed tomography (CT) scan 
 
  
  
DIAGNOSIS: 
 
TREATMENT 
  Surgery 
 Total abdominal hysterectomy 
 Total vaginal hysterectomy 
 Total laparoscopic hysterectomy. 
 Bilateral salpingo-oophorectomy: 
  Radical hysterectomy 
Histopatologic examination: 
      Carcinoma in situ 
 Epithelial tumors 
Endometrioid 
Papillary endometrioid 
Papillary serous 
Clear cell 
Mucinous 
 Mesenchymal tumors 
Endometrial stromal sarcoma 
Leiomyosarcoma 
Nonspecific sarcomas 
 Mixed tumors 
Malignant mixed mullerian 
Adenosarcoma 
 Grade of carcinoma 
 Chemotherapy 
 
 Radiation therapy 
o External pelvic irradiation 
o Vaginal vault irradiation 
o Extended field irradiation 
   Hormone therapy 
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13m
m 
THICK
ENED 
EM 
ENDO 
GR II 
STAGI
NG LP ENDO I 
>5
0 LUS + I A NO 
Y
E
S 
21M
ON alive 
31 RAJESHWARI 66 
008
/12 III 
PMB 
PAIN 16 R 
4
8 M 
DM(
O) NS 
6
9 30 B 
N
D NSIL 
9m
m 
THICK
ENED 
EM 
ENDO 
GR II 
STAGI
NG LP ENDO I 
<5
0 NIL I A NO 
N
O 
21M
ON alive 
32 VASANTHA 53 
012
/12 IV VD 13 IR 
5
0 N NIL NS 
6
1 29 B 
N
D NSIL 
12m
m ND 
ENDO 
GR I 
TAH 
BSO ENDO I 
<5
0 NIL I A NO  
N
O 
15M
ON dead 
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34 RECHAL 61 
43/
12 V PMB 12 IR 
4
5 M 
HYP
O,D
M 
(I) NS 
5
5 25 N 
N
D NSIL 
6m
m 
THICK
ENED 
EM,FL
UID 
COLL 
ENDO 
GR I 
STAGI
NG LP ENDO I 
>5
0 NIL I B NO  
Y
E
S 
19M
ON alive 
35 SARASWATHY 48 
91/
12 V 
PERI 
MB 13 IR _ M NIL NS 
5
6 24 N 
N
D ND 
11m
m, 
poly
p ND 
 ENDO 
GR II 
STAGI
NG LP ENDO III 
>5
0 NIL I B NO 
Y
E
S 
19M
ON dead 
36 VALLI 46 
113
/12 V 
PERI
MB 
PAIN 13 IR _ M NIL NS 
6
7 30 B 
N
D NSIL 
12m
m, 
FIB ND 
PROLIFE
RATIVE 
PHASE 
TAH 
BSO ENDO I 
<5
0 NIL I A NO 
N
O 
18M
ON alive 
37 RAJESHWARI 50 
241
/12 IV 
PERI 
MB 14 R _ M NIL NS 
5
9 28 B 
N
D NSIL 
15m
m ND 
ENDO 
GR I 
STAGI
NG LP ENDO  I 
>5
0 NODES 
III 
C YES 
Y
E
S 
19M
ON alive 
38 BANU 42 
257
/12 III 
PERI 
MB  12 IR _ M NIL NS 
6
0 23 B 
N
D NSIL 
13m
m ND 
COMPLE
X 
HYPERPL
ASIA 
WTH 
NUCLEA
R ATYPIA 
TAH 
BSO ENDO I 
<5
0 NIL I A NO 
N
O 
16M
ON alive 
39 NAGAMMA 54 
262
/12 IV PMB 13 R 
5
2 M NIL NS 
6
1 
24
.5 B 
N
D INFL 
12m
m, 
mas
s MASS 
ENDO 
GR I 
TAH 
BSO ENDO  III 
>5
0 NIL 
I  
B NO 
Y
E
S 
16M
ON dead 
40 KALPANA 45 
273
/12 V 
PERI 
MB,P
AIN 15 IR _ N NIL NS 
7
5 34 N 
N
D NSIL 
21m
m 
THICK
ENED 
EM 
ENDO 
GR II 
TAH 
BSO ENDO  I 
<5
0 NIL IA NO 
N
O 
14M
ON alive 
41 IINDRANI 55 
308
/12 V PMB 16 R 
4
8 M NIL NS 
5
2 
25
.5 N 
N
D NSIL 
11m
m MASS 
POST 
MENOPA
USAL 
STAE 
TAH 
BSO ENDO I 
<5
0 NIL IA NO 
N
O 
14M
ON alive 
42 
SHANTHAKUMA
RI 56 
337
/12 V VD 14 R 
5
2 M 
DM(
I) NS 
6
5 
28
.5 B 
N
D NSIL 
9m
m ND 
PROLIFE
RATIVE 
PHASE 
TAH 
BSO ENDO III 
<5
0 LUS + 
I  
B NO 
R
T 
12M
ON alive 
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43 PANDIAMMAL 67 
341
/12 III VD 13 IR 
4
5 N NIL NS 
5
7 
22
.5 
14 
W
KS 
26
8.
4 INFL 
10m
m 
THICK
ENED 
EM, 
OMN
TAL 
NOD
ULES 
ENDO 
GR I 
STAGI
NG LP ENDO II 
>5
0 
B/LOV
ARAN 
METS 
OMEN
TAL 
DEPOSI
TS 
IV 
B SYS 
N
O 
6MO
N alive 
44 MUNIAMMA 57 
342
/12 V VD 12 R 
5
5 B NIL NS 
6
6 28 B 
N
D NSIL 
9 
mm ND 
ENDO 
GR II 
TAH 
BSO ENDO  II 
<5
0 NIL I A NO  
N
O 
12M
ON alive 
45 SALIMUNISHA 60 
343
/12 V PMB 11 R 
5
8 M 
DM(
O) NS 
8
2 37 N 
N
D NSIL 
10m
m 
THICK
ENED 
EM 
ENDO 
GR II 
TAH 
BSO ENDO I 
<5
0 NIL I A NO 
N
O 
12M
ON alive 
46 RUKMANI 50 
390
/12 V PMB 14 R 
4
6 M HT NS 
6
7 29 N 
N
D NSIL 
14m
m 
thicke
ned 
em,R
T INT 
ILIAC 
NODE
+ 
ENDO 
GR I 
STAGI
NG LP ENDO I 
>5
0 NIL IB NO 
Y
E
S 
11M
ON alive 
47 VASANTHA 63 
410
/12 IV PMB 13 R 
4
8 M HT NS 
8
5 39 N 
N
D NSIL 
25m
m MASS 
ENDO 
GR II 
TAH 
BSO VG II 
>5
0 NIL I B YES 
Y
E
S 
11M
ON alive 
48 RANI 48 
007
/13 IV PMB 14 IR   M NIL NS 
6
7 29 N 
N
D INFL 
11m
m 
MASS
, 
NODE
S 
ENDO 
GR III 
STAGI
NG LP ENDO I 
<5
0 NODES 
III 
C YES 
Y
E
S 
9MO
N alive 
49 AYYAMMAL 65 
33/
13 IV 
PMB 
,VD 16 R 
4
9 M NIL NS 
5
5 
29
.5 N 
N
D NSIL 
13m
m ND VG GR I 
TAH 
BSO VG  I 
<5
0 NIL I A    NO 
N
O 
10M
ON alive 
50 MALLIGA 50 
78/
13 V 
PERI 
MB,V
D 16 IR   N 
HYP
O NS 
7
0 31 B 
N
D ND 
12m
m ND 
ENDO 
GRII 
TAH 
BSO ENDO II 
<5
0 NIL IA NO 
N
O 
9MO
N  alive 
51 PUSHAPAVATHI 65 
87/
13 V LW LA 12 R 
4
5 M 
HT 
DM(
O) NS 
5
0 
25
.5 
AT
R
O
PH
C 
N
D NSIL 
8m
m 
FLUID 
COLL,
LESIO
N 
ENDO 
GR I 
TAH 
BSO ENDO  I 
<5
0 NIL I A NO 
N
O 
9MO
N alive 
52 BERNIE 45 
93/
13 IV 
PERI
MB  13 IR _ M 
DM(
O) NS 
5
8 22 B 
N
D NSIL 
10m
m ND 
ENDO 
GR I 
TAH 
BSO ENDO  I 
<5
0 NIL I A NO 
N
O 
6MO
N alive 
53 JOTHI 61 
92/
13 V 
PMB 
PAIN 16 R 
4
0 M 
DM(
o) NS 
7
2 32 N 
N
D NSIL N 
THICK
ENED 
EM 
ENDO 
GR II 
TAH 
BSO ENDO  I 
<5
0 NIL I A NO 
N
O 
8MO
N alive 
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54 FATHIMA 49 
94/
13 III 
PERI 
MB 11 IR _ M HT NS 
5
8 22 12 
N
D INFL 
13 
mm 
,FIB  ND 
PROLIFE
RATIVE 
PHASE 
TAH 
BSO ENDO I 
<5
0 NIL IA NO 
N
O 
8MO
N alive 
55 NGHTINGALE 52 
96/
13 V VD 15 IR 
5
1 M 
DM(
O) NS 
5
8 23 B 
N
D NSIL 
15m
m 
MASS
,EXT 
ILIAC 
NODE 
ENDO 
GR II 
STAGI
NG LP ENDO I 
>5
0 LUS CX II YES 
Y
E
S 
10 
MO
N alive 
56 INDRANI 54 
124
/13 IV 
PMB,
VD 12 R 
5
3 N 
DM(
O) NS 
7
1 31 N 
N
D NSIL 
17m
m ND 
ENDOGR 
I 
TAH 
BSO ENDO I 
<5
0 NIL I A NO 
N
O 
7MO
N alive 
57 
MANGALAKSHM
I 57 
163
/13 V PMB 15 R 
4
5 M 
DM(
I) NS 
6
9 32 
SI
ZE 
N
OT 
M
A
DE 
O
UT 
N
D NSIL 
20m
m 
AB N 
THICK
ENED 
EM,4
6 mm 
ENDO 
GR II 
TAH 
BSO ENDO III 
<5
0 NIL I B  NO 
Y
E
S 
6MO
N alive 
58 MALLKA 60 
175
/13 V PMB 15 R 
4
5 M NIL NS 
6
8 28 N 
N
D NSIL 
FIB 
17m
m ND 
ENDO 
GR I 
TAH 
BSO ENDO I 
<5
0 NIL I A NO 
N
O 
6MO
N alive 
59 KANNAMA 50 
174
/13 V 
PERI
MB 15 IR _ M 
HYP
O NS 
5
5 
23
.5 N 
N
D NSIL 
15m
m ND 
ENDO 
GRI 
STAGI
NG LP ENDO  II 
>5
0 
OMNT
M 
IV 
B YES 
N
O 
6MO
N alive 
60 CLARRAMMA 62 
253
/13 V 
PMB,
PAIN 15 R 
5
2 M 
DM(
O), 
HT, 
HYP
O NS 
6
7 
29
.5 N 
N
D NSIL 
12m
m MASS 
ENDO 
GR I 
TAH 
BSO ENDO  I 
>5
0 NIL I B NO 
Y
E
S 
6MO
N alive 
61 MANICKAMMAL 70 
263
/13 III PMB 12 R 
5
5 M 
DM(
O) 
HT 
HYP
O NS 
6
9 30 B 
N
D NSIL 
14 
mm ND 
ENDO 
GRII 
TAH 
BSO ENDO II 
<5
0 NIL IA NO 
N
O 
6MO
N alive 
62 KASTHURI 53 
287
/13 II 
VD  
,PAIN 13 IR 
4
9 N 
DM(
O) NS 
7
0 32 B 
N
D NSIL 
11 
mm ND 
ENDO 
GRI 
TAH 
BSO ENDO I 
<5
0 NIL. IA NO 
N
O 
6 
mON alive 
                                                       
  
  
KEY TO MASTER CHART 
PMB  : Post menopausal bleeding 
PERI MB : Perimenopausal bleeding 
VD  : Vaginal discharge 
LW  : Loss of weight 
LOA  : Loss of appetite 
R/IR  : Regular / Irregular 
M/N  : Multiparous / Nulliparous 
DM  : Diabetes Mellitus 
HT  : Hypertension 
HYPO : Hypothyroidism 
NSIL  : Negative for Squamous Intraepithelial Lesion 
INFL  : Inflammatory 
ENDO : Endometrioid adenocarcinoma  
VG  : Villoglandular  
TAH BSO : Total abdominal hysterectomy with bilateral 
   salpingooopherectomy  
ND  : Not done 
NS  : Not significant 
NA  : Not  available / Applicable 
  
  
 
  
  
  
  
PATIENT CONSENT FORM 
Title of the Project 
ENDOMETRIAL CARCINOMA 
A CLINICO PATHOLOGICAL STUDY 
Institution : Institute of Obstetrics & Gynaecology,   
   Egmore,Chennai – 600 008. 
Name  :    Date   : 
Age  :    IP No.  : 
Sex  :    Project Patient No : 
The details of the study have been provided to me in the writing 
and explained to me in my own language. 
I confirm that I have understood the above study and had the 
opportunity to ask questions. 
I understood that my participation in the study is voluntary and 
that I am free to withdraw at any time, without giving any reason, 
without the medical care that will normally be provided by the 
hospital being affected. 
I agree not to restrict the use of any data or results that arise 
from this study provided such a use is only for scientific purpose(s). 
I have been given an information sheet giving details at the 
study 
I fully consent to participate in the above study regarding 
endometrial carcinoma and drug intake before and after surgery. 
 
Name of the Subject  Signature  Date 
Name of the Investigator  Signature  Date 
